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ABSTRACT
Humans usually contract dengue by being bitten by arthropods, and more than 3.6 billion people are at risk per year. Although studies are conducted 
to screen and trace out the possible pathophysiology of the virus, an adequate receptor-based study has not been completed. Understanding how the 
dengue virus (DV) engraves its landing sites requires identification of such cellular receptors. In many model studies, heparan sulfate (HS) has been 
reported to act as a DV receptor under various conditions. However, the physiological relevance of these findings remains uncertain. Therefore, it is 
still unclear whether HS is used by viral strains or not, and if at all used by clinical or non-cell culture-adapted strains of DV. The present review aims 
to identify relevant experimental evidences that confirm the possible interaction between envelope protein and HS chains. We collected data from a 
series of studies to conclude the interactive role.
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INTRODUCTION
Dengue viruses (DV) are members of the flavivirus family primarily 
transmitted to humans by the Aedes aegypti mosquito [1]. Four dengue 
virus serotypes are predominantly infective by any of these predisposes 
individuals to more severe disease following a subsequent infection by 
a different dengue serotype [2,3]. Although strategies to combat dengue 
virus pathogenesis have been developed, it is widely acknowledged that 
pre-existing, non-neutralizing antibodies to dengue viruses enhance 
infection of immune cells and increase the risk of DHF and DSS following 
dengue virus infection [2].
Statistical analysis reveals an estimate of 50 million people being exposed 
to infection by dengue virus annually and approximately 500,000–
1,000,000 infections culminate in dengue hemorrhagic fever (DHF) or 
dengue shock syndrome (DSS), with 5–30% mortality rates [4,5].
Dengue virus is an enveloped virus measuring almost 50 nm in diameter. 
On the viral membrane, the envelope glycoprotein (E protein) is present 
(Fig. 1). The E protein binds to receptors on host membranes and also 
acts as an antigen against host immune response that induces neutralizing 
antibodies to be produced [6]. Proteins are divided into domains I, II, and 
III, referred to as domains I, II, and III, respectively. The hinge region is 
linked to both of the other functional domains. As a result of fluctuations 
in external pH, the E protein structure changes due to the mobility of this 
region. A hydrophobic-rich peptide sequence [7] features membrane fusion 
activity and contributes to dimerization of E proteins in domain II [8].
Domain III is thought to be involved in the binding to receptor molecules 
present on the host cell membrane (Fig. 1). During viral infection, the 
adsorption of viral particles is initiated by binding of E protein to 
receptor molecules present on the host cell membrane. Endocytosis 
is then used to take the viruses into the cell. Through the action of 
an E protein fusion peptide inside endosomes, the pH decreases 
inside endosomes formed by the fusion of lysosomes. Eventually, the 
nucleocapsid enters the cytoplasm, and the virus genome is released 
into the cytoplasm.
Mosquitoes transmit the dengue virus from human to human making 
the virus more efficient to infect and proliferate in both humans and 
mosquitoes as hosts [9]. Several studies have been performed to 
determine the host receptor(s) for dengue virus in the past 30 years. 
Several molecules as such are proposed as possible receptors in human 
and mosquito cells and tissues [10,11].
This process is mediated by envelop proteins (E), which actively bind to 
the dengue virus’ receptor. Cell surfaces of mammals contain Heparan 
sulfate, nLc4Cer, DCSIG, L-SIG, and mannose receptors which bind to 
DEN 1–4 serotypes (Fig. 2). DEN-2 serotype also binds with HSP70/
HSP90, GRP78, and CD14- associated protein. Both the DEN 1–3 
serotypes bind to Laminin receptor bind [12,13].
Among the potential candidates are sulfated glycosaminoglycans 
(GAGs), lectins, glycosphingolipids (GSLs), laminin-binding proteins, 
GSLs, chaperones, and unknown proteins [14]. Diverse studies strongly 
suggest that human dengue virus infection in the absence of heparan 
sulfate and DC-SIGN may result in death. It is thought that heparan 
sulfate functions as a co-receptor, which associates with other molecules 
to form functional complexes and facilitates virus infection [15]. By 
means of DC-SIGN, which is specifically expressed on the cells, DENV 
infects the dendritic cells.
It acts as the main receptor for viruses in the blood after these cells 
move to where they are propagated and disseminated by the peripheral 
lymph nodes [16]. Several studies supported the suggestion that 
carbohydrate molecules in extracellular matrix are strongly related to 
DENV receptors [17].
It is the lack of involvement of GAGs in viral infection of mosquito cells 
that makes it different from mammalian cells. To date, laminin-binding 
proteins, GSLs, and other undefined proteins have been proposed in 
mosquito cells and organs [18]. It appears that the interaction between 
the virus and host cell in mosquitoes is mediated by molecules that 
differ from those found in mammals.
VIRUS ENTRY TO HOST CELLS
Aedes mosquitoes transmit the dengue virus, which is an arthropod-
borne disease. Humans and nonhuman primates are both susceptible to 
dengue fever and hemorrhagic diseases caused by the virus.
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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Dengue disease pathological progression is dependent on direct 
interaction between mosquito-borne virus and the host’s receptor 
molecule(s) [19]. For a better understanding of dengue disease, 
understanding the molecular mechanisms by which dengue virus binds 
to its receptor (or receptors) in humans and mosquitoes is essential. In 
addition, developing effective new dengue therapies requires a thorough 
understanding of the molecular mechanism (s) of viral entry into 
host [20]. Binding of dengue virus to its receptor molecules is mediated 
through a viral envelope glycoprotein, termed E protein [21]. The goal of 
this chapter is to present a summary of dengue virus receptor molecules 
proposed as of yet, including their structures, binding properties, and 
pathological relevance. In mammals, chaperone molecules such as 
phytosphingolipids (TGL) and sulfated glycosaminoglycans (GAGs) are 
potentially receptors for carbohydrates [22]. In addition, several lines 
of evidence suggest that mosquito cells and organs contain a variety of 
receptor molecules, including GSLs, chaperone-like proteins, laminin-
binding proteins, as well as other uncharacterized proteins [23].
MEMBRANE ASSOCIATED PROTEIN (M)
Membrane associated protein is a membrane glycoprotein works as 
a part of nucleocapsid and assists to envelop protein to form mature 
virions. Researchers developed antibodies against prM for Japanese 
encephalitis virus (JEV), West Nile virus (WNV), and dengue virus [24]. 
Dengue viruses and West Nile viruses do not react with antibodies 
against the prM protein of JEV. prM protein can be used to investigate 
differentiating antibody responses to difference flaviviruses [25]. 
Infected Aedes albopictus cells were immunoprecipitated for detection 
of C-prM. Membrane associated protein (M) and non-membrane 
fragments (pr) were produced by these cells.
In mosquito cells, this cleavage was less efficient. Staphylococcal 
protein A was subsequently fused to the fragmented proteins. Rabbit 
antisera were generated from the fusion protein which was stable 
[26]. A domain of the carboxy terminus of the E gene is responsible for 
mediating E-prM interactions in dengue virus, while a peptide in the 
ectodomain of the E gene mediates cell activity in dengue virus [27].
ENVELOPE PROTEIN (E)
Envelop protein present on the surface of the viruses is extremely 
involved in virus attachment with host cell through cell receptors like 
heparin sulfate DCSIGN. It is most important protein for the entry of 
virus into cell [28]. This protein has three domains, domain I (structural 
domain), domain II (dimmers), and domain III (binding domain). 
Dimmer domain links structural and binding domain [29].
An endosome’s reduced pH sets off a conformational change within viral 
envelop proteins, which allows dengue virus to enter a host cell [30]. By 
changing its conformation, the virus is able to merge with the host cell 
membrane [31]. The way that flaviviruses fuse using the E protein’s distal 
barrels is by inserting them into the cell membrane [32]. In the crystal 
structure of E’s soluble ectodermal domain, residues that influence pH for 
fusion is surrounded by a hydrophobic pocket [33]. These hydrophobic 
pockets formed at the junction of two domains open and close at the β 
hair pins. Thus, it can be used in testing antiviral compounds [34].
HEPARAN SULFATE
The highly acidic linear polysaccharide heparan sulfate (HS) has a very 
variable structure. All mammalian tissues and cell surfaces express 
it, along with the extracellular matrix and basement membrane. 
Fig. 2: Image showing the possible receptors for landing of the DENV on the host cell lines. Image retrieved from Sobia Idrees, 2012 [8]
Fig. 1: Diagram showing the protein interaction of DENV with lectin and other molecules expressed on the host cell surface. Diagram 
retrieved from Sobia Idrees, 2012 [8]
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By interacting with diverse polypeptides and exerting diverse 
functions, HS is synthesized to attach to various core proteins to form 
HS-proteoglycans [35]. Heparan sulfate (HS) is a glycosaminoglycan 
(GAG) that is ubiquitously present on cell surfaces, in the extracellular 
matrix (ECM), and in the basement membrane (BM).
Hexuronic acid and d-glucosamine are repeated disaccharides in each 
HS molecule [36]. These units are said to exhibit immense structural 
diversity due to substitutions with sulfate groups [37] (Fig. 1). Mast 
cells only contain HS which is highly sulfated and structurally related to 
heparin but not to HS. ER, Golgi apparatus, and trans Golgi network play 
key roles in HS chain biosynthesis and modification, which ultimately 
results in HS-proteoglycans (HSPG) that are attached to protein cores 
(Fig. 1) [38].
In addition to endoglycosidase and heparanase [39], HS chains can be 
modified by Sulf1 and Sulf2 “endosulfatases.”
HS chains are not essential for the function of core proteins [40], HS 
predominantly dictates the ligand-binding capability and therefore 
the biological roles of HSPG. Moreover, despite the fact that different 
cell types express similar core proteins, the HS chains these core 
proteins carry have markedly different functions, such that HSPG is 
widely distributed within mammalian physiology and has a variety of 
roles [19].
By binding to cytokines, chemokines, growth factors, and morphogens 
at the cell surface, HSPG prevent their degradation, thereby 
creating gradients of temporary stores of morphogens essential for 
development [41]. Besides acting as endocytosis receptors, these 
proteins also act as lysosomal degradation receptors, which ensure 
nutrient delivery to the cell. In addition, they participate in the 
endocytosis of cellular receptors [42]. Chemokines are transported 
across endothelial cells by these proteins. In addition, they act as co-
receptors of fibroblast growth factor (FGF) and FGF receptor, either in 
trans (if expressed on different cells) or cis (if expressed on the same 
cells). On proteolytic breakdown of syndecans, they act as intracellular 
signal transducers. They have an important role in development and 
in maintaining stem cell niches [43]. Angiogenesis, blood coagulation, 
development, and cell homeostasis are among the many activities they 
mediate [R]. Pathogens, particularly viruses, use highly sulfated HSPG 
to attach to cell surfaces [44].
HEPARAN SULFATE PROTEOGLYCANS AS VIRAL RECEPTORS
HSPGs are ubiquitously expressed in most cell types in mammals. 
The heavily sulfated GAG chains present a global negative charge that 
can interact electrostatically with the basic residues of viral surface 
glycoproteins or viral capsid proteins from non-enveloped viruses. 
Weak interactions enable viruses to concentrate on the cell surface and 
bind a more specific entry receptor on the cell surface [45].
It has been observed that human endothelial, liver, and animal cell lines 
interact with the HSPG at various stages of its development [46]. Cell 
lines from insects (C6/36) may also interact with HSPG. Further, DENV 
pseudo particles produced with the E and pre-matrix (prM) proteins 
of viruses never passing through cells have been shown to bind HSPG 
and heparin similarly to viruses that have passed through cell lines 
extensively.
These attachment receptors are first expressed by cell lines expressing 
HSPG. The wide range of tissues (liver, lymph node, spleen, and bone 
marrow) infected with DENV may translate to the variety of receptors 
involved in DENV entry [46].
HSPG was first demonstrated to be binding to DENV in 1997, where HS 
derived from highly sulfated liver and heparin inhibited DENV2 [47].
HS chains have been shown to serve as attachment factors for a variety 
of microorganisms and viruses, including flaviviruses [48]. In multiple 
studies, HS has been shown to play a role in the DV infection process 
[24], suggesting that HS may indeed serve as a receptor or co-receptor 
for DV infection of host cells. Other studies investigating the role of HS 
in DV infection have demonstrated that DV, when propagated under 
certain conditions in vitro, can undergo adaptive changes resulting in 
increased affinity for and utilization of HS for cell infection [49,50]. 
Indeed, similar studies with other flaviviruses, including TBEV and 
JEV, have also shown the potential of these viruses to undergo genetic 
changes on cell culture propagation which also confer an increased HS 
binding phenotype [51].
Studies done by Acharya et al. (2015) stated that DV strains showed 
an enhanced binding to HS after repeatedly passaging in cell lines [52]. 
Artpradit utilized a new technology named recombinant subviral 
particles (RSPs) to screen for the possible role of HS in the DV entry 
into the host cells.
Unlike heparin and HS, RSPs are designed in a way that allows them 
to interact with Vero cells in a similar manner. They used all the four 
strains of DV1 to produce RSPs with their native prM–gpE sequences. 
Identity of the RSPs were examined using Western blot, MALDI-MS, 
and sucrose gradient ultracentrifugation. Furthermore, a substantial 
number of studies have confirmed the positive interaction between HS 
and DV by ELISA and chromatography using immobilized heparin [53]. 
Studies done by Bhatt et al., 2021, also stated that rate of infection 
was also altered on treating the cells with heparinases [1] or soluble 
heparin/HS [54]. HC and soluble heparin inhibited all four strains of 
RSP, as well as infected the DV isolates Studies by Artpradit showed 
all four strains of RSP had symptoms of infection and inhibition by HC 
and HS. These findings collectively prove of the possible interaction 
between DV and HS.
Interestingly, though all RSPs were found to be bound to heparin in 
ELISA studies, the intensity of binding varied across RSP concentrations 
between strains. Strains with low-passage histories showed more 
affinity to heparin than those with high passage strains. ELISA binding 
results also confirmed of a greater interaction between heparin and the 
two RSPs of low-passage strains. High competition rates were found 
between high-passage strain RSPs and low-passage strain RSPs. Low 
passage strains also had relatively higher IC50 values for both heparin 
and HS competition, which states that these RSPs bound more strongly 
to immobilized heparin. These results support the conclusion that 
both low-passage and high-passage strains of DV1 utilize HS as an 
attachment factor [54].
Unlike heparin, HS has a different level of sulfation, which was 
responsible for competing for RSP binding to immobilized heparin 
and inhibiting RSP binding to Vero cells. While other studies 
have found HS as necessary for DV binding and infection [55], 
a few studies have shown that heparin and highly sulfated HS, 
but not unmodified HS, are able to bind DV/gpE and/or inhibit 
infection [56]. In addition to the various strains and serotypes, 
different assay formats were also utilized with our study, which may 
lead to different observations.
Several flaviviruses, including DV2 and DV4, have been shown to undergo 
adaptive changes leading to an enhanced HS-binding phenotype when 
propagated under specific cell culture conditions [57]. Even reports 
from the previous investigations of DV1 confirm that HS is a necessary 
attachment factor for DV1 [57]. Additional viral and biochemical studies 
are needed to elucidate the mechanisms of HS usage by different strains 
and serotypes of DV [58]. A number of HS-mimicking molecules with 
anti-DV activity such as fucoidan, carageenan, DL-galactan, and α-d-
glucans [59] and PI-88 are shown to increase survival in a mouse model 
of DV infection [60].
The previous reports stated that there are two conserved regions 
within the envelope protein primary structure which could bind 
to the heparin. On careful examination of the envelope protein 
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sequence of the dengue 2 virus, two such putative GAG-binding 
motifs were screened one between 284 and 310 and other between 
386 and 411 [60]. P17763 (Dengue virus); A0A142I5B9 (Zika virus); 
P0DOK8 (Japanese encephalitis virus, Strain 38); P06935 (West 
Nile virus); Q32ZE0 (Bussuquara virus); Q32ZD5 (Kokobera virus); 
Q32ZD7 (Ilheus virus, ILHV); P05769 (Murray valley encephalitis 
virus); P14335 (Kunjin virus); P09732 (St. louis encephalitis virus); 
Q5WPU5 (Usutu virus); Q32ZD4 Rocio virus, ROCV); Q074N0 (Yellow 
fever virus); C8XPB2 (Edge Hill virus); C8XPA8 Banzi virus, BANV); 
C5H431 Wesselsbron virus; D7RF80 (Kyasanur forest); Q91B85 
(Alkhumra hemorrhage virus); P29838 (Langat virus); Q7T6D2 
(Omsk hemorrhagic virus); and P35764 (Louping ill virus). About 29 
strains of viruses were screened for their conserved domains within 
the envelope protein.
Within the polyprotein of DENV, 115–280 regions holds Protein prM, 
115–205 region holds Peptide pr, 206–280 holds Small envelope 
protein M and 281–775 holds Envelope protein E. Researchers found 
the two regions responsible for binding to HS [58,61] to be 284 and 310 
[VGIGNRDFVEGLSGATWVDVVLEHGSC] and other between 386 and 
411 [GLFGKGSLITCAKFKCVTKLEGKIVQY]. Clustal omega was used for 
the multiple sequence alignment to screen for the conserved domains 
within the envelope protein regions of all of the above 2 viral strains 
including DENV [P17763].
The multiple sequence alignment results (Figs. 3-5) clearly starts 
that the putative sequence exists among other viral strains also, and 
the conserved domains are found to be within the regions binding to 
the HS. This confirms of the role of interaction between the envelope 
protein domains with the HS chains.
Fig. 4: Multiple sequence alignment of the envelope protein sequences of various viral strains along with dengue virus. Detailed 
representation of black box sequence (horizontal) for myriad proteins [VGIGNRDFVEGLSGATWVDVVLEHGSC] which binds HS. Vertical box 
denotes the conserved domain in all the viral strains
Fig. 3: Dengue virus genome. Dengue virus genome encodes 10 viral proteins including 3 structural proteins (C, M, and E) responsible for 
viral structure and viral attachment to host cell and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) that are 
involved in viral replication and other cellular function
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CONCLUSION
We provide schematic and systematic evidence supporting an 
interaction between HS and envelope protein of DENV. Many studies 
concluded that the envelope protein binds to HS to gain entry into the 
host cells. Similarly, it was determined that HS could also serve as a 
landing site for clinically relevant DV1 strains. Other different evidence-
based approaches need to be studied to for similar interactions. The 
reports available so far, states that HS and envelope protein interact 
positively in a cooperative manner for effective entry into the host cells.
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